ClinicalTrials.gg
Not yet recruitingNCT07817277TrichoscopyDM2Updated Sep 14, 2026

Hair Changes in Females With Type 2 Diabetes Clinical and Trichoscopic Examination

An observational study in Diabete Mellitus, Female Androgenetic Alopecia and Dermoscopy, sponsored by Al-Azhar University. Not yet recruiting at 1 site in Egypt. Open to female participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Al-Azhar University · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
130
Ages
20 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 146 studies in Diabetes Mellitus with a site in Egypt — 32 open to participants now, 41 under way, 2 of them phase 3. Diabetes Mellitus · Egypt.

Planned enrollment
20th of 45
130 · median 108
Started
2026
with 11 others
Observational
45 of 146
16 open now
Primary completion
2027-01
later than 35 of 40 live
Registered
143rd of 146
by date
Lead sponsor
4 of 146
Al-Azhar University

Among the 146 studies in Diabetes Mellitus with a site in Egypt, this one is the 20th largest by planned enrollment of the 45 observational ones that give a count, is one of 12 that started in 2026, is one of 45 observational ones, reaches primary completion later than 35 of the 40 other live ones, and was the 143rd registered.

Diabetes Mellitus

8,294 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

32 of the 146 studies in Diabetes Mellitus with a site in Egypt are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 20 Years to 60 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in Diabetes Mellitus with a site in Egypt, or all of them as a file.
02

Study summary

The aim of this thesis is to investigate the effect of diabetes mellitus on hair by assessing and comparing clinical and dermoscopic hair changes in diabetic patients versus age and sex-matched healthy controls.

Read the detailed description

The patients will be recruited from the dermatology and endocrinology outpatient clinics of Al-Zahraa University Hospital.

Inclusion criteria •

Cases:

Female patients aged 20-60 years Diagnosed with type 2 diabetes mellitus for at least 1 year HbA1c ≥ 6.5% o Consent to participate

  • Controls:

Age-matched healthy females (no history of diabetes or insulin resistance) Normal fasting blood sugar (\<100 mg/dL) and HbA1c (\<5.7%) No known chronic illness Consent to participate Exclusion Criteria (for both groups)

  • Current pregnancy or lactation
  • Thyroid dysfunction
  • Polycystic ovary syndrome (PCOS) • Anemia (Hb \< 10 g/dL)
  • History of chemotherapy, radiotherapy, or recent acute illness
  • Scalp diseases (e.g., tinea capitis, scarring alopecia)
  • Recent use of drugs known to affect hair growth (e.g., isotretinoin, spironolactone)

All patients and control will undergo:

1. Full history taking 2. Clinical Assessment All participants will undergo generalized dermatological examination including the scalp and body hair. The following aspects will be documented: A. General Scalp Examination • Hair density: visual inspection (reduced, normal) • Scalp condition: erythema, scaling, atrophy, scarring • Presence of inflammation or follicular hyperkeratosis • Hair shaft fragility or breakage • Sebum level: dry, normal, oily

B. Hair Loss Type Classification Hair loss will be clinically categorized into one of the following types:

  1. Telogen effluvium (TE) Diffuse shedding, positive hair pull test
  2. Female pattern hair loss (FPHL) Frontal or vertex thinning with preserved frontal hairline
  3. Alopecia areata (AA) Patches of non-scarring alopecia
  4. Chronic diffuse hair loss Shedding >6 months without clear pattern C. Hair Pull Test • Performed by grasping \~50 hairs from the frontal, parietal, and occipital regions • Considered positive if >6 hairs are easily extracted • Helps diagnose active shedding, especially in TE 3. Dermoscopic (Trichoscopic) Assessment Dermoscopy will be performed using a handheld dermoscope ( dermasight DS175 -cutechs LLC, Cairo, Egypt ) at 10× magnification, with or without immersion fluid.

A. Sites Examined

  • Frontal scalp (midline, 2 cm behind hairline)
  • Vertex
  • Occipital region (serves as internal control)

Each site will be examined systematically, and the following features will be documented:

B. Dermoscopic Parameters Hair shaft diameter diversity (HSDD) >20% variation Yellow dots Peripilar signs (brown halos) Short vellus hairs Thin hairs \<30 μm Empty follicular openings Black dots Exclamation mark hairs Broken / dystrophic hairs

4. Blinding and Reproducibility

  • Two independent dermatologists will assess dermoscopic images. • In case of disagreement, a third reviewer will be consulted. • Observers will be blinded to diabetic status to minimize bias.

5. Photographic Documentation • High-resolution digital images of scalp regions 6. Laboratory investigations:

The following laboratory serum tests will be done:

  1. Complete blood count.
  2. serum ferritin.
  3. Thyroid stimulating hormone.
  4. serum vitamin D3.
  5. Erythrocyte sedimentation rate.
  6. Glycated hemoglobin.
03

Conditions studied

  • Diabete Mellitus
  • Female Androgenetic Alopecia
  • Dermoscopy

Browse trials for

Keywords

  • Dermoscopy
  • FPHL
  • DM2
04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The patients will be recruited from the dermatology and endocrinology outpatient clinics of Al-Zahraa University Hospital.

The patients will be recruited from the dermatology and endocrinology outpatient clinics of Al-Zahraa University Hospital.

Inclusion criteria • Cases: o Female patients aged 20-60 years o Diagnosed with type 2 diabetes mellitus for at least 1 year o HbA1c ≥ 6.5% o Consent to participate • Controls: o Age-matched healthy females (no history of diabetes or insulin resistance) o Normal fasting blood sugar (\<100 mg/dL) and HbA1c (\<5.7%) o No known chronic illness o Consent to participate Exclusion Criteria (for both groups) • Current pregnancy or lactation • Thyroid dysfunction • Polycystic ovary syndrome (PCOS) • Anemia (Hb \< 10 g/dL) • History of chemotherapy, radiotherapy, or recent acute illness • Scalp diseases (e.g., tinea capitis, scarring alopecia) • Recent use of drugs known to affect hair growth (e.g., isotretinoin, spironolactone).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cases:

    • Female patients aged 20-60 years
    • Diagnosed with type 2 diabetes mellitus for at least 1 year
    • ≥ 6.5% o Consent to participate

      • Controls:
    • Age-matched healthy females (no history of diabetes or insulin resistance)
    • Normal fasting blood sugar (\<100 mg/dL) and HbA1c (\<5.7%) o No known chronic illness
    • Consent to participate

Exclusion criteria

Exclusion Criteria:

  • Current pregnancy or lactation

    • Thyroid dysfunction • Polycystic ovary syndrome (PCOS)
    • Anemia ( \< 10 g/dL)
    • History of chemotherapy, radiotherapy, or recent acute illness
    • Scalp diseases (e.g., tinea capitis, scarring alopecia)
    • Recent use of drugs known to affect hair growth (e.g., isotretinoin, spironolactone)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
130 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Evaluation of Hair Changes in Female Patients with Type 2 Diabetes Mellitus Versus Non-Diabetic Controls: A Clinical and Dermoscopic Cross-Sectional Study

    Clinical Hair Assessment: 1. Hair loss pattern (diffuse, frontal, vertex, etc.) 2. Duration of hair loss (months/years) 3. Hair pull test results (positive/negative) Dermoscopic (Trichoscopic) Features: 1. Hair shaft diameter variability (%) 2. Presence of yellow dots, white dots, or peripilar signs 3. Follicular density (number/cm²) 4. Miniaturized hair count Metabolic and Laboratory Parameters: 1. BMI (kg/m²) 2. HbA1c (%) 3. Serum Ferritin (ng/mL) 4. Vitamin D3 (ng/mL) 5. TSH (µIU/mL) 6. Hemoglobin (g/dL) 7. ESR (mm/hr) Diabetes-Related Measures: 1. Duration of diabetes (years) 2. Presence of diabetic neuropathy (yes/no) Patient-Reported Outcomes Visual Analog Scale (VAS) for hair loss severity (ludwing scale-sinclair scale) Physician's Global Assessment of hair changes

    Time frame: 1 year

07

Study locations

1 site
  • Al Zahraa hospital
    Cairo, Cairo Governorate, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Jan 2027, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2026
First posted
Sep 14, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07817277
Responsible party
Heba Khaled Younes Mohamed (resident, Al-Azhar University) — Principal investigator
First posted
Sep 14, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Sep 14, 2026

Study contacts

Heba khaled younes, resident
Contact
drmedhatyoness@gmail.com
+201025858377
Basma Alsayed risha, lecturer
principal investigator · Al-Azhar University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion